MedTrace Logo

Pharmacotherapy Follow-up in Older HIV-infected Patients

NCT02763995 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-05-10

No results posted yet for this study

Summary

Cardiovascular diseases (CVD) are the main cause of death in Spain. In HIV patients, the uncontrolled viral replication, antiretroviral therapy (ART) and coinfections contribute to develop metabolic diseases and increase the prevalence of risk factors for CVD. These patients are aging which results in a higher probability of comorbidities, increased number of medications, possibility of having a negative outcome associated with medication (NOM) and increased cardiovascular risk (CVR). Various studies have established that pharmaceutical care (PC) results in better control of cardiovascular risk factors.

The purpose of this study is to evaluate the impact of pharmaceutical care achieved through pharmacotherapy follow-up on cardiovascular risk and health related quality of life (HRQoL) of HIV patients older than 50.

Conditions

Interventions

BEHAVIORAL

Pharmaceutical care

This is a quasi-experimental study and the same group will be evaluated before and after the follow up.

Sponsors & Collaborators

  • Elza Aparecida Machado Domingues

    lead OTHER

Principal Investigators

  • Elza Aparecida M Domingues, MSc · Universidad de Granada

  • Miguel Angel Calleja Hernandez, PhD · University Hospital Virgen de las Nieves

  • Monica Ferrit Martin, PhD · University Hospital Virgen de las Nieves

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763995 on ClinicalTrials.gov